CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year. The post CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on…

Read More

A Reality Check on SDOH: Challenges We Can’t Ignore

A very small percentage of health outcomes are tied to direct healthcare activities. The non-medical factors, conditions in which people are born, grow, live, and work in, more often than not, impact health outcomes more than the clinical care they receive. The post A Reality Check on SDOH: Challenges We Can’t Ignore appeared first on…

Read More